Avalo Therapeutics (AVTX) Accumulated Depreciation & Amortization (2016 - 2025)
Avalo Therapeutics (AVTX) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $710000.0 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 31.0% year-over-year to $710000.0, compared with a TTM value of $710000.0 through Dec 2024, up 31.0%, and an annual FY2024 reading of $710000.0, up 31.0% over the prior year.
- Accumulated Depreciation & Amortization was $710000.0 for Q4 2024 at Avalo Therapeutics, up from $542000.0 in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $710000.0 in Q4 2024 and bottomed at $177000.0 in Q4 2020.
- Average Accumulated Depreciation & Amortization over 5 years is $425800.0, with a median of $414000.0 recorded in 2022.
- The sharpest move saw Accumulated Depreciation & Amortization crashed 95.44% in 2020, then surged 61.58% in 2021.
- Year by year, Accumulated Depreciation & Amortization stood at $177000.0 in 2020, then soared by 61.58% to $286000.0 in 2021, then soared by 44.76% to $414000.0 in 2022, then skyrocketed by 30.92% to $542000.0 in 2023, then skyrocketed by 31.0% to $710000.0 in 2024.
- Business Quant data shows Accumulated Depreciation & Amortization for AVTX at $710000.0 in Q4 2024, $542000.0 in Q4 2023, and $414000.0 in Q4 2022.